Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Dr. Mark Peters
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
age ≥ 18years of age at the time of procedure
- patients with localized lipodystrophy in the medial or lateral thigh, and visible cellulite of laxity in the lower extremity or buttocks
- BodyTite treatments performed from January 2018 - May 2019 for Cellulite indication
Exclusion Criteria:
- active infection, collagen disorders, immunocompromised state, medications that mitigate inflammatory response, and propensity for keloid/hypertrophic scaring. o BodyTite treatments performed from March 2018 - May 2019 for lipodystrophy and cellulite of laxity
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Photonumeric Cellulite Severity Score
Time Frame: [ Time Frame: Baseline to 6 months posttreatment]
|
Change in Photonumeric Cellulite Severity Score 3. Investigator assessment of the cellulite improvement comparing pre and post treatment using Global aesthetic improvement 5-point grading scale (0=No change, 1=1%-24%%, 2=25%-49%, 3=50%-74% improvement, and 4=75%-100%) at all follow up visits.
|
[ Time Frame: Baseline to 6 months posttreatment]
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mark Petrs, MD
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DO609568A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cellulite
-
NCT07202013CompletedCellulite of Thighs
-
NCT03446781CompletedEdematous Fibrosclerotic Panniculopathy (Cellulite)
-
NCT02127723Completed
-
NCT01321268TerminatedCellulite (Orange Peel Skin)
-
NCT01562470Completed
-
NCT01026441TerminatedCircumference Reduction | Cellulite Reduction
-
NCT05405062Not yet recruitingEfficacy of Treatment of Cellulite Using Carboxy Therapy
-
NCT03782545CompletedTreatment for Cellulite on the Stomach and Flanks
-
NCT03428750CompletedEdematous Fibrosclerotic Panniculopathy (Cellulite)